Orlando Wholesale, L.L.C. Denial of Application, 71555-71557 [E6-20981]
Download as PDF
Federal Register / Vol. 71, No. 237 / Monday, December 11, 2006 / Notices
or recurrence of material injury to an
industry in the United States within a
reasonably foreseeable time.
Background
The Commission instituted these
reviews on January 3, 2006 (71 FR 138)
and determined on April 10, 2006 that
it would conduct full reviews (71 FR
23947, April 25, 2006). Notice of the
scheduling of the Commission’s reviews
and of a public hearing to be held in
connection therewith was given by
posting copies of the notice in the Office
of the Secretary, U.S. International
Trade Commission, Washington, DC,
and by publishing the notice in the
Federal Register on July 17, 2006 (71 FR
40543). The hearing was held in
Washington, DC, on September 19,
2006, and all persons who requested the
opportunity were permitted to appear in
person or by counsel.
The Commission transmitted its
determinations in these reviews to the
Secretary of Commerce on December 6,
2006. The views of the Commission are
contained in USITC Publication 3892
(December 2006), entitled Silicon Metal
from Brazil and China: Investigation
Nos. 731–TA–471 and 472 (Second
Review).
By order of the Commission.
Issued: December 6, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E6–21007 Filed 12–8–06; 8:45 am]
BILLING CODE 7020–02–P
Drug Enforcement Administration
[OMB Number 1117–0042]
Agency Information Collection
Activities: Proposed Collection;
Comments Requested
60-Day Notice of Information
Collection Under Review; National
Clandestine Laboratory Seizure Report.
mstockstill on PROD1PC61 with NOTICES
ACTION:
The Department of Justice (DOJ), Drug
Enforcement Administration (DEA), has
submitted the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies. Comments
are encouraged and will be accepted
until February 9, 2007. This process is
conducted in accordance with 5 CFR
1320.10.
15:15 Dec 08, 2006
of their law enforcement duties and
responsibilities.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: There are ninety-two (92) total
respondents for this information
collection. Seven thousand three
hundred twenty-eight (7328) responded
using paper at 1 hour a response and
one thousand one hundred sixty-three
(1163) responded electronically at 1
hour a response, for eight thousand four
hundred ninety-one (8491) annual
responses.
(6) An estimate of the total public
burden (in hours) associated with the
collection: It is estimated that there are
8491 annual burden hours associated
with this collection.
If additional information is required
contact: Lynn Bryant, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Patrick Henry Building,
Suite 1600, 601 D Street NW.,
Washington, DC 20530.
Dated: December 6, 2006.
Lynn Bryant,
Department Clearance Officer, Department of
Justice.
[FR Doc. E6–21006 Filed 12–8–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Overview of This Information
Collection
DEPARTMENT OF JUSTICE
VerDate Aug<31>2005
If you have comments, especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
please contact Clark R. Fleming, Field
Division Counsel, El Paso Intelligence
Center, 11339 SSG Sims Blvd., El Paso,
TX 79908.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
71555
Jkt 211001
Orlando Wholesale, L.L.C. Denial of
Application
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
National Clandestine Laboratory Seizure
Report.
(3) Agency form number, if any and
the applicable component of the
Department sponsoring the collection:
Form number: EPIC Form 143.
Component: El Paso Intelligence
Center, Drug Enforcement
Administration, U.S. Department of
Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: State, Local or Tribal
Government.
Other: None.
Abstract: Records in this system are
used to provide clandestine laboratory
seizure information to the El Paso
Intelligence Center, Drug Enforcement
Administration, and other Law
enforcement agencies, in the discharge
On November 18, 2005, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Orlando Wholesale,
L.L.C., of Orlando, Florida
(Respondent). The Show Cause Order
proposed to deny Respondent’s pending
application for a DEA Certificate of
Registration as a distributor of List I
chemicals on the ground that its
registration would be inconsistent with
the public interest. See 21 U.S.C. 823(h)
and 824(a).
The Show Cause Order specifically
alleged that Respondent was proposing
to distribute List I chemical products
containing pseudoephedrine, a
precursor chemical which is used to
manufacture methamphetamine, to
convenience stores in the Orlando area
and that methamphetamine
manufacturers often obtain the chemical
from convenience stores. See Show
Cause Order at 1–2. The Show Cause
Order alleged that during DEA’s pre-
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
E:\FR\FM\11DEN1.SGM
11DEN1
71556
Federal Register / Vol. 71, No. 237 / Monday, December 11, 2006 / Notices
mstockstill on PROD1PC61 with NOTICES
registration investigation, investigators
had determined that one of
Respondent’s co-owners had previously
been involved in a firm that distributed
List I chemicals without obtaining a
proper registration. See id. The Show
Cause Order further alleged that DEA
Diversion Investigators (DIs) had
requested that Respondent’s owner
provide them with information
regarding his immigration status, his
business licenses, and the nature of the
co-owner’s involvement in Respondent.
See id. The Show Cause Order alleged
that Respondent had failed to provide
any of the requested information. See id.
On November 25, 2005, the
Government attempted to serve the
Show Cause Order on Respondent by
certified mail, return receipt requested,
at the address of its proposed registered
location, 9500 Satellite Blvd., #230,
Orlando, FL. The mailing was returned
with a notation that Respondent’s
forwarding address was 1167 Doss Ave.,
Orlando, FL. Thereafter, on December
30, 2005, two DEA DIs went to the latter
address and personally served
Respondent’s owner, Mr. Shakil Isani,
with the Show Cause Order. Since that
time, neither Respondent, nor anyone
purporting to represent it, has
responded. Because (1) more than thirty
days have passed since Respondent’s
receipt of the Show Cause Order, and (2)
no request for a hearing has been
received, I conclude that Respondent
has waived its right to a hearing. See 21
CFR 1309.53(c). I therefore enter this
final order without a hearing based on
relevant material found in the
investigative file and make the
following findings.
Findings
Pseudoephedrine is a List I chemical
that, while having a therapeutic use, is
easily extracted from lawful products
and used in the illicit manufacture of
methamphetamine, a schedule II
controlled substance. See 21 U.S.C.
802(34); 21 CFR 1308.12(d). As noted in
numerous DEA orders,
‘‘methamphetamine is an extremely
potent central nervous system
stimulant.’’ Sujak Distributors, 71 FR
50102, 50103 (2006); A–1 Distribution
Wholesale, 70 FR 28573 (2005).
Methamphetamine is highly addictive;
its abuse has destroyed lives and
families and ravaged communities.
Moreover, because of the toxic nature of
the chemicals used to make the drug, its
manufacture creates serious
environmental harms. David M. Starr,
71 FR 39367 (2006).
Respondent is a Florida corporation
which has been in business since
October 2003. On March 22, 2004,
VerDate Aug<31>2005
15:15 Dec 08, 2006
Jkt 211001
Respondent applied for a registration as
a distributor of List I chemicals and gave
as the address of its proposed registered
location: 9500 Satellite Blvd., # 230,
Orlando, FL. On June 15, 2004, two DEA
DIs conducted a pre-registration
investigation at this address. At some
point thereafter, Respondent changed its
address to 1167 Doss Avenue, Orlando.
Respondent did not, however, notify
DEA.
During the pre-registration
investigation, the DIs met with
Respondent’s owner, Mr. Shakil Isani.
Mr. Isani told the DIs that Respondent
is a wholesale distributor of some 700
different items to approximately 109
convenience stores in the greater
Orlando area. Mr. Isani further advised
the DIs that he is the owner and only
officer of Respondent. When the DIs
asked Mr. Isani for a copy of
Respondent’s Articles of Incorporation,
Mr. Isani stated that three other
individuals were listed as being
managing members of the firm but that
he planned on removing them. One of
these individuals had previously come
to the attention of DEA because he was
operating a business (on behalf of his
brother who had been convicted of
several federal criminal offenses and
was then serving a sentence of
incarceration) which distributed List I
chemicals without a valid DEA
registration.
The DIs asked Mr. Isani to provide
them with documentation regarding the
removal of the other members of his
firm. The DIs also asked Mr. Isani for
personal data such as date, place of
birth, and social security numbers for
the other members. Mr. Isani agreed to
provide the information. Mr. Isani has
not, however, provided the information.
The DIs also asked Mr. Isani about his
immigration status. Mr. Isani told the
DIs that he was in the country under a
work permit but that he did not have the
documentation on him. The DIs then
asked Mr. Isani to provide them with
documentation of his status.
Subsequently, the DIs conducted a
check of Mr. Isani’s status and
determined that he was not legally in
the United States and appeared to be
subject to removal proceedings. The
check, however, also showed that Mr.
Isani had applied for an adjustment of
status to become a resident alien.
According to the investigative file, Mr.
Isani has not provided the DIs with
updated information on his status.
During the on-site inspection, the DIs
also asked Mr. Isani to provide copies of
his business licenses. Again, Mr.Isani
has not provided any of the information
that the DIs requested.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Discussion
Under 21 U.S.C. 823(h), an applicant
to distribute List I chemicals is entitled
to be registered unless the registration
would be ‘‘inconsistent with the public
interest.’’ In making this determination,
Congress directed that I consider the
following factors:
(1) Maintenance by the applicant of
effective controls against diversion of listed
chemicals into other than legitimate
channels;
(2) Compliance by the applicant with
applicable Federal, State, and local law;
(3) Any prior conviction record of the
applicant under Federal or State laws relating
to controlled substances or to chemicals
controlled under Federal or State law;
(4) Any past experience of the applicant in
the manufacture and distribution of
chemicals; and
(5) Such other factors as are relevant to and
consistent with the public health and safety.
Id.
‘‘These factors are considered in the
disjunctive.’’ Joy’s Ideas, 70 FR 33195,
33197 (2005). I may rely on any one or
a combination of factors, and may give
each factor the weight I deem
appropriate in determining whether an
application for registration should be
denied. See, e.g., Starr, 71 FR at 39367;
Energy Outlet, 64 FR 14269 (1999).
Moreover, I am ‘‘not required to make
findings as to all of the factors.’’ Hoxie
v. DEA, 419 F.3d 477, 482 (6th Cir.
2005); Morall v. DEA 412 F.3d 165, 173–
74 (D.C. Cir. 2005).
Here, I conclude that an analysis of
each factor is unnecessary and that
Respondent’s application should be
denied for two reasons. First,
Respondent’s owner has failed to submit
necessary information regarding three
issues: (1) His business licenses, (2) his
immigration status, and (3) the role of
persons listed as managing members of
the firm including one individual who
has previously come to the attention of
DEA. Second, Respondent changed its
address—without notifying DEA—and
after the on-site inspection was
conducted.
DEA regulations expressly provide
that ‘‘[t]he Administrator may require an
applicant to submit such documents
* * * relevant to the application as
[she] deems necessary to determine
whether the application should be
granted.’’ 21 CFR 1309.35. The
information sought by the DIs regarding
Respondent’s business licenses and its
owner’s immigration status was
reasonably necessary to evaluate
Respondent’s compliance with
applicable laws. See 21 U.S.C. 823(h)(2).
In light of Respondent’s failure to
produce this information (as well as the
information contained in the
E:\FR\FM\11DEN1.SGM
11DEN1
Federal Register / Vol. 71, No. 237 / Monday, December 11, 2006 / Notices
mstockstill on PROD1PC61 with NOTICES
investigative file), I conclude that
Respondent was not in compliance with
federal immigration laws and that
Respondent does not possess the
required state and/or local business
licenses. Moreover, the information
sought with respect to Respondent’s
managing members was essential to
evaluate whether the firm would
maintain ‘‘effective controls against
diversion.’’ Id. § 823(h)(1). Based on the
information contained in the
investigative file that one of
Respondent’s managing members had
previously operated a business which
distributed List I chemicals without a
valid registration and Respondent’s
failure to provide any documentation
showing that this individual no longer
has a management or ownership interest
in it, I conclude that Respondent does
not maintain effective control against
diversion.
Respondent’s change of address
provides further reason to deny its
application. Under the Controlled
Substances Act, a registration is location
specific. See 21 U.S.C. 822(e) (‘‘A
separate registration shall be required at
each principal place of business * * *
where the applicant * * * distributes
* * * list I chemicals.’’). Respondent
applied for a registration at 9500
Satellite Blvd., # 230, Orlando, Fl. It was
at this location that the pre-registration
investigation was conducted and the
adequacy of Respondent’s security
controls was evaluated. See 21 CFR
1309.71(b). Respondent’s change of its
location after DEA conducted the preregistration inspection renders moot the
information obtained regarding its
security measures and its application for
registration at its prior place of business.
Furthermore, Respondent has not
submitted an application for its new
location. Because Respondent applied to
distribute List I chemicals from the
Satellite Blvd. location and it is no
longer in business at that location, I
conclude that granting its application
for a registration would be inconsistent
with the public interest.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(h), and 28 CFR
0.100(b) & 0.104, I hereby order that the
application of Respondent Orlando
Wholesale L.L.C., for a DEA Certificate
of Registration as a distributor of List I
chemicals be, and it hereby is, denied.
This order is effective January 10, 2007.
Dated: December 1, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6–20981 Filed 12–8–06; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
15:15 Dec 08, 2006
Jkt 211001
Findings
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Taby Enterprises of Osceola, Inc.;
Denial of Application
On November 23, 2005, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Taby Enterprises of
Osceola, Inc., of Plant City, Florida
(Respondent). The Show Cause Order
proposed to deny Respondent’s pending
application for a DEA Certificate of
Registration as a distributor of the List
I chemicals ephedrine and
pseudoephedrine on the ground that its
registration would be inconsistent with
the public interest. See 21 U.S.C. 823(h)
& 824(a).
The Show Cause Order specifically
alleged that Respondent was proposing
to distribute List I chemical products to
convenience stores, which are nontraditional retailers of these products.
See Show Cause Order at 2. The Show
Cause Order further alleged that
Respondent had no experience in the
distribution of List I chemical products.
See id. The Show Cause Order also
alleged that Respondent provided a
customer list which he represented as
including his ‘‘established customers.’’
Id. The Show Cause Order alleged,
however, that when DEA investigators
contacted these establishments, several
‘‘were out of business’’ and only a small
number of them ‘‘expressed any interest
in acquiring listed chemical products
from’’ Respondent. Id. The Show Cause
Order thus alleged that Respondent had
‘‘not provided complete and accurate
information to DEA,’’ and that DEA
therefore could not determine whether
Respondent would comply with federal
law and protect against the diversion of
listed chemical products. Id.
The Show Cause Order was served by
certified mail, return receipt requested.
On December 3, 2005, Respondent
acknowledged receipt of the Show
Cause Order as evidenced by the signed
Return Receipt Card. Since that time,
neither Respondent, nor anyone
purporting to represent it, has
responded. Because (1) More than thirty
days have passed since Respondent’s
receipt of the Show Cause Order, and (2)
no request for a hearing has been
received, I conclude that Respondent
has waived its right to a hearing. See 21
CFR 1309.53(c). I therefore enter this
final order without a hearing based on
relevant material found in the
investigative file and make the
following findings.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
71557
Ephedrine and pseudoephedrine are
List I chemicals that, while having
therapeutic uses, are easily extracted
from lawful products and used in the
illicit manufacture of
methamphetamine, a schedule II
controlled substance. See 21 U.S.C.
802(34); 21 CFR 1308.12(d). As noted in
numerous DEA orders,
‘‘methamphetamine is an extremely
potent central nervous system
stimulant.’’ Sujak Distributors, 71 FR
50102, 50103 (2006); A–1 Distribution
Wholesale, 70 FR 28573 (2005).
Methamphetamine abuse has destroyed
lives and families and ravaged
communities. Moreover, because of the
toxic nature of the chemicals used to
make the drug, its manufacture creates
serious environmental harms. David M.
Starr, 71 FR 39367 (2006).
Respondent is a Florida corporation
which is located at 1912 Jim Redman
Parkway, Plant City, Fl., 33566.
Respondent has been in business since
December 2002; its President and
Owner is Mr. Muhammad Aslam Butt.
On May 2, 2005, Respondent applied
for a registration as a distributor of the
List I chemicals pseudoephedrine and
ephedrine. Thereafter, on June 17, 2005,
two DEA Diversion Investigators (DIs)
went to Respondent’s proposed
registered location to conduct a preregistration investigation. The DIs
inspected Respondent’s facility and
interviewed Respondent’s owner.
The DIs determined that Respondent
sells sundry items including tobacco
products, lighters, various over-thecounter drugs, batteries and small toys,
etc., to local convenience stores and gas
stations. Respondent also operates a
retail store at the same location.
During the interview, Respondent
informed the DIs that he wanted to
expand his product line to include cold
medicines that contain
pseudoephedrine such as Advil, Nyquil/
Dayquil, Tylenol Sinus, Tylenol Cold,
Contact and Tylenol Flu. Respondent
also told the DIs that he intended to sell
Mini-Thins Two Way and other
ephedrine products. Mr. Butt further
stated that he would be the only
individual who would handle List I
chemical products and that he would
purchase the products from F & S
Distributing, Inc., and Price Master
Corp.
According to the investigative file,
Mr. Butt has no prior experience in the
wholesale distribution of List I
chemicals. Moreover, Mr. Butt told the
DIs that he does not verify the identity
of his customers by asking them to
present an ID.
E:\FR\FM\11DEN1.SGM
11DEN1
Agencies
[Federal Register Volume 71, Number 237 (Monday, December 11, 2006)]
[Notices]
[Pages 71555-71557]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20981]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Orlando Wholesale, L.L.C. Denial of Application
On November 18, 2005, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause to Orlando Wholesale, L.L.C., of Orlando, Florida
(Respondent). The Show Cause Order proposed to deny Respondent's
pending application for a DEA Certificate of Registration as a
distributor of List I chemicals on the ground that its registration
would be inconsistent with the public interest. See 21 U.S.C. 823(h)
and 824(a).
The Show Cause Order specifically alleged that Respondent was
proposing to distribute List I chemical products containing
pseudoephedrine, a precursor chemical which is used to manufacture
methamphetamine, to convenience stores in the Orlando area and that
methamphetamine manufacturers often obtain the chemical from
convenience stores. See Show Cause Order at 1-2. The Show Cause Order
alleged that during DEA's pre-
[[Page 71556]]
registration investigation, investigators had determined that one of
Respondent's co-owners had previously been involved in a firm that
distributed List I chemicals without obtaining a proper registration.
See id. The Show Cause Order further alleged that DEA Diversion
Investigators (DIs) had requested that Respondent's owner provide them
with information regarding his immigration status, his business
licenses, and the nature of the co-owner's involvement in Respondent.
See id. The Show Cause Order alleged that Respondent had failed to
provide any of the requested information. See id.
On November 25, 2005, the Government attempted to serve the Show
Cause Order on Respondent by certified mail, return receipt requested,
at the address of its proposed registered location, 9500 Satellite
Blvd., 230, Orlando, FL. The mailing was returned with a
notation that Respondent's forwarding address was 1167 Doss Ave.,
Orlando, FL. Thereafter, on December 30, 2005, two DEA DIs went to the
latter address and personally served Respondent's owner, Mr. Shakil
Isani, with the Show Cause Order. Since that time, neither Respondent,
nor anyone purporting to represent it, has responded. Because (1) more
than thirty days have passed since Respondent's receipt of the Show
Cause Order, and (2) no request for a hearing has been received, I
conclude that Respondent has waived its right to a hearing. See 21 CFR
1309.53(c). I therefore enter this final order without a hearing based
on relevant material found in the investigative file and make the
following findings.
Findings
Pseudoephedrine is a List I chemical that, while having a
therapeutic use, is easily extracted from lawful products and used in
the illicit manufacture of methamphetamine, a schedule II controlled
substance. See 21 U.S.C. 802(34); 21 CFR 1308.12(d). As noted in
numerous DEA orders, ``methamphetamine is an extremely potent central
nervous system stimulant.'' Sujak Distributors, 71 FR 50102, 50103
(2006); A-1 Distribution Wholesale, 70 FR 28573 (2005). Methamphetamine
is highly addictive; its abuse has destroyed lives and families and
ravaged communities. Moreover, because of the toxic nature of the
chemicals used to make the drug, its manufacture creates serious
environmental harms. David M. Starr, 71 FR 39367 (2006).
Respondent is a Florida corporation which has been in business
since October 2003. On March 22, 2004, Respondent applied for a
registration as a distributor of List I chemicals and gave as the
address of its proposed registered location: 9500 Satellite Blvd.,
230, Orlando, FL. On June 15, 2004, two DEA DIs conducted a
pre-registration investigation at this address. At some point
thereafter, Respondent changed its address to 1167 Doss Avenue,
Orlando. Respondent did not, however, notify DEA.
During the pre-registration investigation, the DIs met with
Respondent's owner, Mr. Shakil Isani. Mr. Isani told the DIs that
Respondent is a wholesale distributor of some 700 different items to
approximately 109 convenience stores in the greater Orlando area. Mr.
Isani further advised the DIs that he is the owner and only officer of
Respondent. When the DIs asked Mr. Isani for a copy of Respondent's
Articles of Incorporation, Mr. Isani stated that three other
individuals were listed as being managing members of the firm but that
he planned on removing them. One of these individuals had previously
come to the attention of DEA because he was operating a business (on
behalf of his brother who had been convicted of several federal
criminal offenses and was then serving a sentence of incarceration)
which distributed List I chemicals without a valid DEA registration.
The DIs asked Mr. Isani to provide them with documentation
regarding the removal of the other members of his firm. The DIs also
asked Mr. Isani for personal data such as date, place of birth, and
social security numbers for the other members. Mr. Isani agreed to
provide the information. Mr. Isani has not, however, provided the
information.
The DIs also asked Mr. Isani about his immigration status. Mr.
Isani told the DIs that he was in the country under a work permit but
that he did not have the documentation on him. The DIs then asked Mr.
Isani to provide them with documentation of his status. Subsequently,
the DIs conducted a check of Mr. Isani's status and determined that he
was not legally in the United States and appeared to be subject to
removal proceedings. The check, however, also showed that Mr. Isani had
applied for an adjustment of status to become a resident alien.
According to the investigative file, Mr. Isani has not provided the DIs
with updated information on his status.
During the on-site inspection, the DIs also asked Mr. Isani to
provide copies of his business licenses. Again, Mr.Isani has not
provided any of the information that the DIs requested.
Discussion
Under 21 U.S.C. 823(h), an applicant to distribute List I chemicals
is entitled to be registered unless the registration would be
``inconsistent with the public interest.'' In making this
determination, Congress directed that I consider the following factors:
(1) Maintenance by the applicant of effective controls against
diversion of listed chemicals into other than legitimate channels;
(2) Compliance by the applicant with applicable Federal, State,
and local law;
(3) Any prior conviction record of the applicant under Federal
or State laws relating to controlled substances or to chemicals
controlled under Federal or State law;
(4) Any past experience of the applicant in the manufacture and
distribution of chemicals; and
(5) Such other factors as are relevant to and consistent with
the public health and safety.
Id.
``These factors are considered in the disjunctive.'' Joy's Ideas,
70 FR 33195, 33197 (2005). I may rely on any one or a combination of
factors, and may give each factor the weight I deem appropriate in
determining whether an application for registration should be denied.
See, e.g., Starr, 71 FR at 39367; Energy Outlet, 64 FR 14269 (1999).
Moreover, I am ``not required to make findings as to all of the
factors.'' Hoxie v. DEA, 419 F.3d 477, 482 (6th Cir. 2005); Morall v.
DEA 412 F.3d 165, 173-74 (D.C. Cir. 2005).
Here, I conclude that an analysis of each factor is unnecessary and
that Respondent's application should be denied for two reasons. First,
Respondent's owner has failed to submit necessary information regarding
three issues: (1) His business licenses, (2) his immigration status,
and (3) the role of persons listed as managing members of the firm
including one individual who has previously come to the attention of
DEA. Second, Respondent changed its address--without notifying DEA--and
after the on-site inspection was conducted.
DEA regulations expressly provide that ``[t]he Administrator may
require an applicant to submit such documents * * * relevant to the
application as [she] deems necessary to determine whether the
application should be granted.'' 21 CFR 1309.35. The information sought
by the DIs regarding Respondent's business licenses and its owner's
immigration status was reasonably necessary to evaluate Respondent's
compliance with applicable laws. See 21 U.S.C. 823(h)(2). In light of
Respondent's failure to produce this information (as well as the
information contained in the
[[Page 71557]]
investigative file), I conclude that Respondent was not in compliance
with federal immigration laws and that Respondent does not possess the
required state and/or local business licenses. Moreover, the
information sought with respect to Respondent's managing members was
essential to evaluate whether the firm would maintain ``effective
controls against diversion.'' Id. Sec. 823(h)(1). Based on the
information contained in the investigative file that one of
Respondent's managing members had previously operated a business which
distributed List I chemicals without a valid registration and
Respondent's failure to provide any documentation showing that this
individual no longer has a management or ownership interest in it, I
conclude that Respondent does not maintain effective control against
diversion.
Respondent's change of address provides further reason to deny its
application. Under the Controlled Substances Act, a registration is
location specific. See 21 U.S.C. 822(e) (``A separate registration
shall be required at each principal place of business * * * where the
applicant * * * distributes * * * list I chemicals.''). Respondent
applied for a registration at 9500 Satellite Blvd., 230,
Orlando, Fl. It was at this location that the pre-registration
investigation was conducted and the adequacy of Respondent's security
controls was evaluated. See 21 CFR 1309.71(b). Respondent's change of
its location after DEA conducted the pre-registration inspection
renders moot the information obtained regarding its security measures
and its application for registration at its prior place of business.
Furthermore, Respondent has not submitted an application for its new
location. Because Respondent applied to distribute List I chemicals
from the Satellite Blvd. location and it is no longer in business at
that location, I conclude that granting its application for a
registration would be inconsistent with the public interest.
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(h), and 28
CFR 0.100(b) & 0.104, I hereby order that the application of Respondent
Orlando Wholesale L.L.C., for a DEA Certificate of Registration as a
distributor of List I chemicals be, and it hereby is, denied. This
order is effective January 10, 2007.
Dated: December 1, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6-20981 Filed 12-8-06; 8:45 am]
BILLING CODE 4410-09-P